Last reviewed · How we verify
NCT05764109: ANGELICA
Adherence to Cied Implantation Guidelines and Cardiac Rehabilitation
trial in Left Ventricular Systolic Dysfunction in 488 participants. Completed in 28 January 2025.
29 December 2023
Quick facts
| Lead sponsor | Istituti Clinici Scientifici Maugeri SpA |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 488 |
| Start date | 15 September 2019 |
| Primary completion | 29 December 2023 |
| Estimated completion | 28 January 2025 |
| Sites | 1 location across Italy |
Conditions studied
- Left Ventricular Systolic Dysfunction — all drugs for Left Ventricular Systolic Dysfunction →
- Myocardial Infarction — all drugs for Myocardial Infarction →
Sponsor
Istituti Clinici Scientifici Maugeri SpA
Who can join
Adults 18 to 90, any sex, with Left Ventricular Systolic Dysfunction or Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
There are limited data on how the guideline indications for ICD implantation are applied in clinical practice across Europe. Moreover, the impact of "time-dependence" of some indications to implantation on the guidelines adherence is still unknown. Objective of the present observational study is the evaluation of the adherence to the scientific guidelines in patients with a time-dependent indication to ICD/CRT-D implantation admitted to an in-hospital cardiac rehabilitation program.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05764109
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Left Ventricular Systolic Dysfunction
Currently open trials in the same condition.
- NCT07188805 — A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Bo · Phase 3 · recruiting
- NCT06270498 — Effect of Oral sucRosomIal Iron on exerciSE Capacity and Quality of Life in Patients With Heart Failure · Phase 4 · recruiting
- NCT06221891 — Early Evaluation of Left Ventricular Systolic Function Impairment in Patients With Chronic Kidney Disease by Multimodal · recruiting
- NCT05714085 — Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricula · Phase 2, PHASE3 · recruiting
- NCT05647577 — The Relationship Between Inflammatory ARTritis and CArdiac DIseAse · active not recruiting
Other Istituti Clinici Scientifici Maugeri SpA trials
Trials by the same sponsor.
- NCT07521436 — Awareness of Risk Factors and Perception of Cardiovascular Risk in Secondary Prevention Among Women and Men · not yet recruiting
- NCT07451977 — Effects of Oxygen Supplementation During the 6-Minute Walk Test in Chronic Respiratory Failure or Exertional Hypoxemia · NA · recruiting
- NCT07448181 — Real-life Ecological Momentary Assessment of Lived Burden in Hereditary AngioEdema · recruiting
- NCT07432204 — Therapeutic Music Listening in Post Stroke Patients. · NA · recruiting
- NCT07399418 — TRIAD - Tracking Risk in Integrated Alzheimer's Diagnostics. · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05764109 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituti Clinici Scientifici Maugeri SpA
- Last refreshed: 29 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05764109.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing